Skip to main content
Premium Trial:

Request an Annual Quote

U.S. Genomics Takes License to Locked Nucleic Acid from Exiqon

NEW YORK, April 14 (GenomeWeb News) - U.S. Genomics has licensed locked nucleic acid technology from Exiqon, the companies said today.


Under the global licensing agreement, U.S. Genomics will incorporate locked nucleic acid chemistries from Copenhagen, Denmark-based Exiqon into reagent kits for its Trilogy platform for the analysis of single molecules.


U.S. Genomics, based in Woburn, Mass., plans to include LNA into reagent kits in the third quarter of this year. The first application will be to measure small RNAs, according to the company.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.